Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology

M H A Jansen, D G van Vuurden, W P Vandertop, G J L Kaspers

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

Samenvatting

Patients with diffuse intrinsic pontine gliomas (DIPG) have a poor prognosis. Although DIPG constitute only 10-15% of all pediatric brain tumors, they are the main cause of death in this group. Despite 26 clinical trials in newly diagnosed DIPG in the past 5years (including several targeted agents), there is no clear improvement in prognosis. However, knowledge on DIPG biology is increasing, mainly due to the (re)introduction of biopsies and autopsies, the possibility of gene expression profiling, and the development of in vivo models. Translation of this knowledge into clinical trials in combination with improved drug distribution methods may eventually lead to more effective treatment of this devastating disease.

Originele taal-2Engels
Pagina's (van-tot)27-35
Aantal pagina's9
TijdschriftCancer treatment reviews
Volume38
Nummer van het tijdschrift1
DOI's
StatusGepubliceerd - feb. 2012
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology'. Samen vormen ze een unieke vingerafdruk.

Citeer dit